C
CTI Biopharma | Cell Therapeutics
CTI BioPharma | Seeking to Bring New Options to Patients with Blood Cancers
About CTI Biopharma | Cell Therapeutics
CTI BioPharma Corp. is a biopharmaceutical entity that has been acquired by Sobi, a Swedish Orphan Biovitrum AB, in a transaction valued at approximately $1.7 billion, which was completed in June 2023. Prior to this acquisition, the company, originally founded as Cell Therapeutics, Inc. in 1991 by James A. Bianco, was dedicated to the development and commercialization of targeted therapies for blood-related cancers. The company's primary asset is VONJO® (pacritinib), an oral kinase inhibitor.
VONJO is specifically approved for the treatment of adult patients with intermediate or high-risk primary or secondary myelofibrosis, a rare type of bone marrow cancer, who have a low platelet count (thrombocytopenia). The U.S. Food and Drug Administration (FDA) granted this treatment an accelerated approval in February 2022, a significant milestone for the company as it addressed an unmet medical need for this patient population. The drug functions by inhibiting JAK2, IRAK1, and CSF1R, which are involved in the signaling pathways that contribute to myelofibrosis.
The company's business model revolved around the research, development, and subsequent commercialization of its pharmaceutical products. Revenue was primarily generated from the sales of its approved drug, VONJO. The acquisition by Sobi was a strategic move to leverage Sobi's global presence and resources to enhance the commercialization and reach of pacritinib. The deal was structured as an all-cash tender offer for all outstanding shares of CTI BioPharma.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 1997
- Outcome tier
- Unicorn$1–10B valuation tier
News
Open roles
CTI Biopharma | Cell Therapeutics in the Seattle ecosystem
The CTI Biopharma | Cell Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later3 investors entered at this stage
Inc.
Hercules Capital
NEA
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
7 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about CTI Biopharma | Cell Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CTI Biopharma | Cell Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

